Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · IEX Real-Time Price · USD
2.050
+0.180 (9.63%)
May 2, 2024, 4:00 PM EDT - Market closed
Palatin Technologies Revenue
Palatin Technologies had revenue of $7.10M in the twelve months ending December 31, 2023, with 146.20% growth year-over-year. Revenue in the quarter ending December 31, 2023 was $2.03M with 98.18% year-over-year growth. In the fiscal year ending June 30, 2023, Palatin Technologies had annual revenue of $4.85M with 230.53% growth.
Revenue (ttm)
$7.10M
Revenue Growth
+146.20%
P/S Ratio
4.66
Revenue / Employee
$208,756
Employees
34
Market Cap
33.08M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
Jun 30, 2019 | 60.30M | -6.83M | -10.18% |
Jun 30, 2018 | 67.13M | 22.41M | 50.11% |
Jun 30, 2017 | 44.72M | - | - |
Jun 30, 2016 | 0 | - | - |
Jun 30, 2015 | 12.95M | - | - |
Jun 30, 2014 | 0 | - | - |
Jun 30, 2013 | 10.36K | -63.38K | -85.95% |
Jun 30, 2012 | 73.74K | -1.40M | -95.00% |
Jun 30, 2011 | 1.48M | -12.71M | -89.60% |
Jun 30, 2010 | 14.18M | 2.83M | 24.92% |
Jun 30, 2009 | 11.35M | -131.51K | -1.15% |
Jun 30, 2008 | 11.48M | -2.92M | -20.29% |
Jun 30, 2007 | 14.41M | -5.34M | -27.05% |
Jun 30, 2006 | 19.75M | 1.79M | 9.98% |
Jun 30, 2005 | 17.96M | 15.64M | 675.64% |
Jun 30, 2004 | 2.32M | 1.05M | 82.29% |
Jun 30, 2003 | 1.27M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nutex Health | 247.65M |
Spectral AI | 18.06M |
DURECT | 8.55M |
NeuroOne Medical Technologies | 2.82M |
bioAffinity Technologies | 2.53M |
Femasys | 1.07M |
Pluri | 357.00K |
PTN News
- 1 day ago - Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity - PRNewsWire
- 3 days ago - Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 - PRNewsWire
- 25 days ago - Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 - PRNewsWire
- 2 months ago - Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) - PRNewsWire
- 2 months ago - Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 - PRNewsWire
- 3 months ago - Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) - PRNewsWire
- 3 months ago - Palatin Announces Closing of $10 Million Registered Direct Offering - PRNewsWire